Balaxi Pharmaceuticals Ltd

Balaxi Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Balaxi Pharmaceuticals Ltd

₹ 576 0.03%
26 Apr 10:28 a.m.
balaxiventures.in NSE : BALAXI
About

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]

Key Points

Product Portfolio
Balaxi Pharmaceuticals Limited has a rich portfolio of 610 pharmaceutical product registrations. The pharma product portfolio of the company includes Tablets (46%), Injectables(17%), Liquids (12%), Capsules (13%), and Others (12%). The pharma products are sourced from WHO-GMP certified contract manufacturers based in India, China, and Portugal. [1] [2] [3]

Website NSE
  • Market Cap ₹ 627 Cr.
  • Current Price ₹ 576
  • High / Low ₹ 686 / 400
  • Stock P/E 19.2
  • Book Value ₹ 152
  • Dividend Yield 0.00 %
  • ROCE 38.5 %
  • ROE 32.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 47.3%
  • Debtor days have improved from 71.3 to 56.7 days.

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Trading Industry: Trading

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
66 53 58 70 62 89 83 86 87 81 66 55 61
54 43 47 56 48 78 69 72 71 68 57 44 47
Operating Profit 12 10 11 14 14 11 14 15 15 13 9 11 14
OPM % 18% 19% 20% 20% 22% 13% 17% 17% 18% 16% 13% 20% 22%
0 -0 1 0 -0 4 3 4 -5 -0 -48 6 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 1 0 1 0
Profit before tax 12 10 12 14 13 15 17 19 11 11 -39 16 14
Tax % 10% 16% 14% 14% 6% 15% 15% 17% 22% 27% -5% 8% 5%
11 8 11 12 12 13 14 15 8 8 -41 14 14
EPS in Rs 10.95 8.36 10.71 12.05 12.18 12.71 14.15 15.49 8.21 7.96 -40.41 14.11 13.28
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
14 46 231 279 336 262
12 37 189 229 279 216
Operating Profit 2 8 43 51 57 46
OPM % 11% 18% 18% 18% 17% 18%
1 1 2 5 3 -40
Interest 0 0 0 1 1 1
Depreciation 0 0 0 1 2 3
Profit before tax 2 9 44 55 57 2
Tax % 19% 31% 14% 13% 19%
2 6 38 48 46 -5
EPS in Rs 6.48 6.10 38.14 47.66 45.14 -5.06
Dividend Payout % 0% 0% 0% 1% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 95%
TTM: -24%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 96%
TTM: -35%
Stock Price CAGR
10 Years: %
5 Years: 45%
3 Years: -1%
1 Year: 9%
Return on Equity
10 Years: %
5 Years: %
3 Years: 47%
Last Year: 32%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 3 10 10 10 10 10
Reserves 0 18 55 103 162 145
0 0 4 4 13 19
3 8 31 60 54 40
Total Liabilities 6 36 100 176 240 214
0 0 2 29 41 43
CWIP 0 0 0 1 3 0
Investments 0 0 3 0 0 0
6 36 94 147 195 171
Total Assets 6 36 100 176 240 214

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-2 -14 0 34 6
-0 -0 -6 -28 -11
0 18 4 -0 26
Net Cash Flow -2 4 -2 6 21

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 147 238 121 36 57
Inventory Days 9 29 184 189
Days Payable 64 53 92 62
Cash Conversion Cycle 147 183 97 129 184
Working Capital Days 82 181 96 97 133
ROCE % 57% 93% 60% 39%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Apr 2024
72.86% 72.86% 72.86% 72.86% 72.86% 72.69% 71.57% 71.22% 71.22% 71.22% 66.86% 66.36%
0.00% 0.00% 0.00% 0.00% 19.00% 18.95% 18.66% 18.57% 18.57% 18.57% 17.21% 17.08%
19.48% 19.48% 19.31% 19.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.02% 0.02%
7.65% 7.64% 7.83% 8.11% 8.11% 8.33% 9.75% 10.18% 10.18% 10.18% 15.91% 16.54%
No. of Shareholders 4,1423,8713,9884,1764,8004,7304,8595,1235,0475,0455,2065,132

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls